Coherus Will Reveal Tagmokitug Clinical Data on October 28
The company plans to release interim Phase 1b/2a trial results for its CCR8 antibody during a scheduled investor webcast.
Updated on Oct. 14, 2026 in Biotech
Live Poll
Do you trust pharmaceutical companies to be transparent with clinical trial data results?
On October 28, 2026, Coherus Oncology will host a webcast to disclose interim clinical data for its tagmokitug program. The study, currently in Phase 1b/2a, evaluates the cytolytic CCR8 antibody in combination with toripalimab across multiple solid tumor types.
Why it matters
The upcoming results will offer insight into the efficacy of tagmokitug, a novel therapeutic approach targeting the CCR8 receptor, as the company explores its performance against solid tumors like head and neck squamous cell carcinoma and colorectal cancer.
Tagmokitug is a cytolytic CCR8 antibody, a class of therapeutics that targets C-C motif chemokine receptor 8 to potentially induce tumor-killing activity. The interim data release will provide early performance markers from ongoing Phase 1b/2a clinical trials.
The players
Coherus Oncology
A biopharmaceutical company headquartered in Redwood City, California, specializing in oncology therapeutics and the commercialization of immune checkpoint inhibitors.
The details
The program investigates the co-administration of tagmokitug with toripalimab, a PD-1 blocking antibody commercialized under the registered trademark LOQTORZI. Tagmokitug acts as a cytolytic agent—a substance that destroys cells—by targeting CCR8 receptors typically expressed on regulatory T cells within the tumor microenvironment. This study aims to determine how this combination therapy impacts solid tumor progression in patients.
Timeline
Coherus will disclose interim clinical data on October 28, 2026.
The management webcast is scheduled for 4:30 p.m. to 6:00 p.m. Eastern Daylight Time on October 28, 2026.
The Tech Race
The development of CCR8-targeting therapies is a current competitive focus in immuno-oncology as researchers seek to modulate the tumor microenvironment. This disclosure marks a data-driven milestone in the broader race to validate CCR8 as a target for improving immune-based cancer treatments.
This event primarily concerns investors and clinicians tracking the clinical progress of novel oncology therapeutics. Stakeholders must pre-register through the company's portal to obtain the dial-in credentials and PIN required for the October 28 live discussion.
The takeaway
The upcoming webcast provides the first opportunity to benchmark the efficacy of the tagmokitug combination therapy against current immuno-oncology standards. Observers should track the Phase 1b/2a data points for objective response rates in the identified solid tumor patient cohorts.
What happens next
Coherus Oncology will host a live webcast for investors and analysts to discuss the tagmokitug data on October 28, 2026, from 4:30 p.m. to 6:00 p.m. Eastern Daylight Time.
Further reading
Learn more about the latest developments in immuno-oncology and drug development in our Biotech section.
More information
To register for the live event, visit the webcast registration and dial-in portal.
Live Poll
Do you trust pharmaceutical companies to be transparent with clinical trial data results?
